MedTrace Logo

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2026-04-01

No results posted yet for this study

Summary

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.

Conditions

Interventions

DRUG

Atezolizumab - 28 Day Cycle

Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.

DRUG

Bevacizumab

Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.

DRUG

Ipatasertib

Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.

DRUG

Talazoparib

Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.

DRUG

Trastuzumab emtansine

Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.

DRUG

Tiragolumab

Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.

DRUG

Atezolizumab - 21 Day Cycle

Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.

DRUG

Inavolisib

Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.

DRUG

Letrozole

Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.

DRUG

Giredestrant

Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.

DRUG

Abemaciclib

Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2026-10-01
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04486352 on ClinicalTrials.gov